Biologic Therapies for Allergic Rhinitis and Nasal Polyposis

Geng, Bob; Dilley, Michelle; Anterasian, Christine

doi:10.1007/s11882-021-01013-y

Cited by 20 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the type 2/T helper type 2 cell-mediated allergic CRS mouse model, IL-4, IL-5, and IL-13 were increased. These increased cytokines were also implicated in allergic and metabolic conditions, such as allergic rhinitis, obesity, diabetes, and MS, 35,[37][38][39] which can partially explain our results.…”

Section: Patient Characteristicssupporting

confidence: 56%

Analysis of risk factors affecting olfactory dysfunction in patients with chronic rhinosinusitis: Highlighting the role of metabolic syndrome

Zhang

Wang

et al. 2023

Laryngoscope Investig Oto

View full text Add to dashboard Cite

Objective This study aims to evaluate the relationship between chronic sinusitis (CRS) and metabolic syndrome (MS) in a Chinese population and to explore the risk factors for olfactory dysfunction in patients with CRS. Methods A total of 387 CRS patients were enrolled. Olfactory function was assessed by the Sniffin’ Sticks 12‐item test and MS was diagnosed according to the guidelines. Logistic regression analysis was performed on CRS patients to screen independent risk factors of olfactory dysfunction, adjusted for confounding factors. Results Among 387 patients, average age of visit and duration of onset were 48.7 years and 1.8 years, respectively. The prevalence of MS was 15.0%. CRS patients with MS were more likely to be older (51.2 vs. 46.8, p = .004), predominantly male (p < .001) and have a higher proportion of olfactory dysfunction (62.1% vs. 44.1%, p = .018) than those without MS. In multivariate logistic regression analysis, MS was associated with olfactory dysfunction in CRS patients (OR: 2.06, 95% CI: 1.14–3.72, p = .016). This association remained significant after controlling for confounding factors. In addition, nasal polyps (OR: 13.41, 95% CI: 8.11–22.17, p < .001) and allergic rhinitis (OR: 3.16, 95% CI: 1.67–5.99, p < .001) were also risk factors for olfactory dysfunction after adjusting for confounding factors. Conclusions MS is associated with olfactory dysfunction in patients with CRS. MS, nasal polyps, and allergic rhinitis are risk factors for olfactory dysfunction in CRS patients. Level of evidence IV

show abstract

Section: Patient Characteristicssupporting

confidence: 56%

Analysis of risk factors affecting olfactory dysfunction in patients with chronic rhinosinusitis: Highlighting the role of metabolic syndrome

Zhang

Wang

et al. 2023

Laryngoscope Investig Oto

View full text Add to dashboard Cite

show abstract

“…The exact pathophysiology of nasal polyposis is not completely explained, but recent studies demonstrated that it involves cytokines such as IL-5, IL-4 and IL-13. Levels of IgE are often elevated in patients with nasal polyp tissue [ 24 ]. In recent years there has been a growing number of papers showing the efficacy of omalizumab for severe nasal inflammation in adults [ 25 , 26 , 27 ].…”

Section: Resultsmentioning

confidence: 99%

An Overview of Off-Label Use of Humanized Monoclonal Antibodies in Paediatrics

2022

View full text Add to dashboard Cite

In recent years, off-label and unlicensed drug use has extensively developed in the paediatric population. For a long time, clinical trials in the paediatric population were considered complicated to perform because of ethical problems, causing frequent off-label use. Off-label drug use remains an important public health issue, especially for children with rare conditions or with diseases not responsive to conventional treatments. The present paper is a narrative review of the literature of off-label drug use in children. The aim of our study is to summarize the main works dealing with the off-label use of biological drugs in paediatrics. Further studies analyzing their efficacy, safety, and cost–benefit ratios are needed to extend the use of biological therapies to the paediatric population.

show abstract

“…Dupilumab treatment has been shown to reduce the need for surgery, oral corticosteroid use, and improves SNOT-22 and EQ VAS scores. 4,5 Prescribers could consider other biologics such as omalizumab or mepolizumab, which have been shown to have similar efficacy in clinical trials, 6 and only require reconstitution with sterile water rather than refrigeration, which may be better suited to an austere environment.…”

Section: Discussionmentioning

confidence: 99%